Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients
Genes · 2024
DOI: 10.3390/genes15060818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Ella G Markalunas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Brown University, Providence, RI 02912, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Galectins, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Prisma Health transformative seed grant, 2022 ASPIREinG seed grant from the USC School of Medicine Greenville.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Galectins are innate immune system regulators associated with disease progression in cancer. This paper aims to investigate the correlation between mutated cancer-critical genes and galectin levels in breast cancer patients to determine whether galectins and genetic profiles can be used as biomarkers for disease and potential therapy targets. Prisma Health Cancer Institute’s Biorepository provided seventy-one breast cancer samples, including all four stages spanning the major molecular subtypes and histologies. Hotspot mutation statuses of cancer-critical genes were determined using multiplex PCR in tumor samples from the same patients by Precision Genetics and the University of South Carolina Functional Genomics Core Facility. The galectin-1, -3, and -9 levels in patients’ sera were analyzed using Enzyme-linked Immunosorbent Assay (ELISA). An analysis was performed using JMP software to compare mean and median serum galectin levels between samples with and without specific cancer-critical genes, including pooled t-test, Wilcoxon Rank Sum Test, ANOVA, and Steel Dwass Test (α=0.05). Our analysis indicates that KIT mutations correlate with elevated serum levels of galectin-9 in patients with breast cancer. In patients with Luminal A subtype, FLT3 mutation correlates with lower serum galectin-1 and -9 levels and TP53 mutations correlate with higher serum galectin-3 levels. Patients with invasive ductal carcinoma had significantly higher serum galectin-3 levels than patients with ductal carcinoma in situ. Patients with both TP53 and PIK3CA mutations exhibit elevated serum galectin-3 levels, while patients with one or neither mutation show no significant difference in serum galectin-3 levels. In addition, metastatic breast cancer samples were more likely to have a KIT or PIK3CA mutation compared to primary breast cancer samples. The relationship between genetic mutations and galectin levels has the potential to identify appropriate candidates for combined therapy, targeting genetic mutations and galectins. Further understanding of the effect of genetic mutations and galectin levels on cancer progression and metastasis could aid in the search for biomarkers for breast cancer diagnosis, disease progression, and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Brown University, Providence, RI 02912, USA.
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA.
- Prisma Health Cancer Institute, Prisma Health, Greenville, SC 29605, USA.
- Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA.
- Department of Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA.
ORCID-Profile: Ella G Markalunas, Avery T Funkhouser, Julie C Martin, Michael Shtutman, W Jeffery Edenfield, Anna V Blenda
Förderung
- NIGMS NIH HHS
- Prisma Health transformative seed grant
- 2022 ASPIREinG seed grant from the USC School of Medicine Greenville
- Brown SPRINT LINK Award from Brown University
- Functional Genomics Core of the COBRE Center
Zitieren
APA
Markalunas, E. G., Arnold, D. H., Funkhouser, A. T., Martin, J. C., Shtutman, M., Edenfield, W. J., & Blenda, A. V. (2024). Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. Genes. https://doi.org/10.3390/genes15060818
Vancouver
Markalunas EG, Arnold DH, Funkhouser AT, Martin JC, Shtutman M, Edenfield WJ, et al. Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. Genes. 2024. doi:10.3390/genes15060818
BibTeX
@article{Markalunas2024,
author = {Markalunas, Ella G and Arnold, David H and Funkhouser, Avery T and Martin, Julie C and Shtutman, Michael and Edenfield, W Jeffery and Blenda, Anna V},
title = {Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15060818}
}
EUVIMED